Thursday, May 12, 2016 3:24:05 PM
BSSP/Canteck Pharma 8-K filed with SEC:
http://www.sec.gov/Archives/edgar/data/1495028/000159406216000450/0001594062-16-000450-index.htm
http://www.sec.gov/Archives/edgar/data/1495028/000159406216000450/form8k.htm
On April 19, 2016, Two Billion Two Hundred Twenty Million Eight Hundred Sixty Three Thousand Four Hundred and Four (2,220,863,404) shares of
the Company’s Common Restricted Stock were agreed to be issued to Canteck Pharma, Inc., representing 54.05% of the issued and
outstanding shares of Common Stock, in behalf of the Purchase Agreement with Cantech.
The shares shall have non dilutable provisions.
BSSP/
Canteck Pharma Sales Agreement filed with the SEC:
http://www.sec.gov/Archives/edgar/data/1495028/000159406216000450/ex101.htm
Two Billion Two Hundred Twenty Million Eight Hundred Sixty Three Thousand Four Hundred and Four (2,220,863,404) (the “Purchase Shares”) of REVE TECHNOLOGIES, INC.(“BSSP”) restricted common shares.
The Purchase Shares are to carry a non-dilutable designation.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM